Home / Business and Economy / UPS Invests $48M in Cold Chain for Weight-Loss Drugs
UPS Invests $48M in Cold Chain for Weight-Loss Drugs
23 Jun
Summary
- UPS invests $48 million to enhance temperature-controlled facilities.
- Demand for weight-loss drugs is rapidly increasing in the U.S.
- New facilities will support delivery of sensitive medications globally.
UPS announced a significant $48 million investment to upgrade its temperature-controlled facilities, a move driven by the escalating demand for weight-loss drugs. This expansion aims to secure the supply chain for GLP-1 medications and other sensitive pharmaceuticals. The company is enhancing 27 facilities globally, located in the Americas, Europe, and Asia. These sites are designed to maintain precise temperature ranges crucial for biologics, vaccines, and specialized treatments, preventing spoilage and ensuring patient access.
This strategic investment by UPS addresses a growing market trend, with approximately 12 percent of U.S. adults currently using GLP-1 drugs for weight loss or chronic condition management. The global market for transporting and storing temperature-sensitive biologics is substantial, valued at $19.7 billion in 2024 and projected to grow significantly. UPS's enhanced capabilities are expected to solidify its position in the healthcare logistics sector, which generated $3 billion in revenue for the company in the first quarter of 2026.
